Revvity (RVTY)

NYSEHealth CareMedical - Diagnostics & ResearchSnapshot 2026-10-15

$152.64-1.34%

Close 2026-10-16 · 1-day change

Read the published Living FV report summary

Investment OutlookAs of Oct 15, 2026

What could strengthen or challenge Revvity’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

+0.1%

+10% or more+5%0%−5%−10% or less

5.89 → 5.89 EPS · FY ending Dec 28, 2027 · 9 analysts

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

Change in the same fiscal period’s mean EPS estimate from Sep 15, 2026 to Oct 15, 2026: (new ÷ prior − 1). Contributor count changed from 8 to 9; this is not the number of analysts revising. Source: FMP consensus snapshots. The ±10% axis is a display range.

Living FV™

Living Fair Value by QuarterlyIQ

A valuation that evolves as the business changes.

A published Living FV snapshot is not available yet. The valuation workflow remains discoverable; a market target cannot supply the missing evidence.

View Living FV report and workflow

What the Thesis Depends On

Three key conditions need to be met for the investment thesis to play out.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
adjusted EPS of $5.20-$5.30 for 2026	It targets adjusted EPS near $5.25 in 2026.	Intact	adjusted EPS falls below $5.00 in FY26	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 15, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 of last 3 quarters. Management updated full year 2026 pro forma adjusted EPS guidance from $5.20-$5.30 to $5.30-$5.40. Quarterly diluted EPS increased from $0.36 in Q1 to $0.47 in Q2 2026, showing positive earnings trajectory consistent with guidance. The company is reiterating this EPS target consistently. Delivery assessment Oct 15, 2026
divestiture of China Immunodiagnostics business (6% of 2025 revenue)	A supporting condition in Revvity's published investment case. The stated target is successful divestiture completed without material revenue loss beyond 6%.	Improving	divestiture delays or revenue loss exceeds 6% of 2025 revenue	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 15, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 2 of last 2 quarters. Management announced the strategic divestiture of the China Immunodiagnostics business, which accounted for approximately 6% of 2025 revenue. The divestiture is expected to complete in 2027 after regulatory approvals. The company has provided pro forma financials excluding this business, indicating active execution on this priority. Delivery assessment Oct 15, 2026
organic revenue growth of 3%-4% in 2026	A primary condition in Revvity's published investment case. The stated target is 3%-4% YoY.	Broken	organic revenue growth falls below 2% in FY26	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 15, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 of last 3 quarters. Management forecasts pro forma organic revenue growth of 3%-4% for 2026, up from initial 2%-3% guidance in 2025-Q4. Revenue showed modest growth trends with pro forma revenue around $2.08B in 2025 nine months and $1.44B in 2026 six months, indicating progress but mixed trajectory. Overall, management is maintaining this growth target consistently. Delivery assessment Oct 15, 2026

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-28 · fmp

FY2027 EPS$5.89

$5.81 → $5.89 · observed estimates

FY2027 revenue$3.01B

$2.98B → $3.01B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$5.81	$2,976,833,822	7 / 9
2026-07-25	$5.81	$2,976,833,822	7 / 9
2026-07-26	$5.81	$2,976,833,822	6 / 9
2026-07-27	$5.81	$2,976,833,822	6 / 9
2026-07-28	$5.81	$2,976,833,822	6 / 9
2026-07-29	$5.81	$2,976,833,822	6 / 9
2026-07-30	$5.81	$2,976,833,822	6 / 9
2026-07-31	$5.81	$2,976,833,822	6 / 9
2026-08-01	$5.81	$2,976,833,822	6 / 9
2026-08-02	$5.81	$2,976,833,130	7 / 9
2026-08-03	$5.81	$2,976,833,130	7 / 9
2026-08-04	$5.81	$2,976,833,130	7 / 9
2026-08-05	$5.81	$2,976,833,130	7 / 9
2026-08-06	$5.81	$2,976,833,130	7 / 9
2026-08-08	$5.91	$3,003,509,575	8 / 9
2026-08-09	$5.91	$3,003,509,575	8 / 9
2026-08-10	$5.91	$3,003,509,575	8 / 9
2026-08-12	$5.91	$3,003,509,575	8 / 9
2026-08-13	$5.91	$3,003,509,575	8 / 9
2026-08-14	$5.91	$3,003,509,575	8 / 9
2026-08-15	$5.91	$3,003,509,575	8 / 9
2026-08-16	$5.91	$3,003,509,575	8 / 10
2026-08-17	$5.91	$3,003,509,575	8 / 10
2026-08-18	$5.91	$3,003,509,575	8 / 10
2026-08-19	$5.91	$3,003,509,575	8 / 10
2026-08-20	$5.88	$3,003,509,575	8 / 10
2026-08-21	$5.88	$3,003,509,575	8 / 10
2026-08-22	$5.88	$3,003,509,575	8 / 10
2026-08-23	$5.88	$3,003,509,575	8 / 10
2026-08-24	$5.88	$3,003,509,575	8 / 10
2026-08-25	$5.88	$3,003,509,575	8 / 10
2026-08-26	$5.88	$3,003,509,575	8 / 10
2026-08-27	$5.88	$3,003,509,575	8 / 10
2026-08-28	$5.88	$3,003,509,575	8 / 10
2026-08-29	$5.88	$3,003,502,932	8 / 10
2026-08-30	$5.88	$3,003,502,932	8 / 10
2026-08-31	$5.88	$3,003,502,932	8 / 10
2026-09-01	$5.88	$3,003,502,932	8 / 10
2026-09-02	$5.88	$3,004,411,537	8 / 10
2026-09-03	$5.88	$3,004,411,537	9 / 11
2026-09-04	$5.88	$3,004,734,470	9 / 11
2026-09-05	$5.88	$3,004,734,470	9 / 11
2026-09-06	$5.88	$3,004,734,470	9 / 11
2026-09-07	$5.88	$3,004,734,470	8 / 11
2026-09-08	$5.88	$3,004,734,470	8 / 11
2026-09-09	$5.88	$3,004,734,470	8 / 11
2026-09-10	$5.89	$3,003,817,981	8 / 11
2026-09-11	$5.89	$3,003,817,981	8 / 11
2026-09-12	$5.89	$3,003,817,981	8 / 11
2026-09-13	$5.89	$3,003,817,981	8 / 11
2026-09-14	$5.89	$3,003,817,981	8 / 11
2026-09-15	$5.89	$3,003,817,981	8 / 11
2026-09-16	$5.89	$3,003,817,981	8 / 11
2026-09-17	$5.89	$3,003,817,981	8 / 11
2026-09-18	$5.89	$3,003,817,981	8 / 11
2026-09-19	$5.89	$3,003,817,981	8 / 11
2026-09-20	$5.89	$3,003,817,981	8 / 11
2026-09-21	$5.89	$3,003,817,981	8 / 11
2026-09-22	$5.89	$3,003,817,981	8 / 11
2026-09-23	$5.89	$3,003,817,981	8 / 11
2026-09-24	$5.89	$3,003,817,981	8 / 11
2026-09-25	$5.89	$3,003,817,981	8 / 11
2026-09-26	$5.89	$3,003,817,981	8 / 11
2026-09-27	$5.89	$3,003,817,981	8 / 11
2026-09-28	$5.89	$3,003,817,981	8 / 11
2026-09-29	$5.88	$3,003,942,169	8 / 11
2026-09-30	$5.88	$3,003,942,169	8 / 11
2026-10-01	$5.88	$3,004,948,117	8 / 10
2026-10-02	$5.88	$3,004,948,117	8 / 10
2026-10-03	$5.88	$3,004,948,117	8 / 10
2026-10-04	$5.88	$3,004,948,117	8 / 10
2026-10-05	$5.88	$3,004,948,117	8 / 10
2026-10-06	$5.88	$3,004,948,117	8 / 10
2026-10-07	$5.89	$3,005,191,576	8 / 10
2026-10-08	$5.88	$3,005,191,576	8 / 11
2026-10-09	$5.89	$3,005,305,132	8 / 11
2026-10-10	$5.89	$3,005,305,132	8 / 11
2026-10-11	$5.89	$3,005,305,132	8 / 11
2026-10-12	$5.89	$3,005,305,132	9 / 12
2026-10-13	$5.89	$3,005,305,132	9 / 12
2026-10-14	$5.89	$3,006,531,798	9 / 12
2026-10-15	$5.89	$3,006,501,474	9 / 12

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	7	9	0
2026-06-01	7	11	0
2026-07-01	6	11	0
2026-08-01	6	11	0
2026-09-01	6	13	1
2026-10-01	6	11	1

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 6 Buy / Strong Buy · 11 Hold · 1 Sell / Strong Sell

0 upgrades0 downgrades2 maintains

Recent actions · Sep 16–Oct 15 · 2 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

BarclaysOct 7 · prior Apr 14

$95.00 → $160.00+68.4%

$0$88.00$176.00

1 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 16, 2026–Oct 15, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

adjusted EPS of $5.20-$5.30 for 2026Direct metric needs a verified mapping
divestiture of China Immunodiagnostics business (6% of 2025 revenue)Direct metric needs a verified mapping
organic revenue growth of 3%-4% in 2026Published status: Broken

Next proof point

Nov 3, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

1.3%Typical daily move · historical

Downside history

-30.1%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Revvity outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 10, 2026

What kind of bet this is

This investment represents a durable compounder with a focus on consistent revenue growth and earnings stability. The current thesis state is intact, as recent financial performance remains strong within its industry.

What's priced into Revvity

The market appears to price RVTY at a premium compared to its peers, indicating high expectations for future performance. This premium suggests that investors are anticipating continued strong results, but there may be an expectations gap that could be tested if performance falters.

What the fundamentals likely do

Management is on track to achieve its revenue and earnings targets for 2026, with recent results showing positive trends. However, there is moderate risk due to potential economic headwinds that could impact performance.

What Revvity hinges on

Key factors include the company's ability to execute on its divestiture strategy and maintain its growth targets. Additionally, the performance of sector bellwethers and overall economic conditions will play a significant role in RVTY's trajectory.